Product
TPI 287
3 clinical trials
3 indications
Indication
Glioblastoma MultiformeIndication
NeuroblastomaIndication
MedulloblastomaClinical trial
Phase 1/2 Dose-Escalation Study of TPI 287 in Combination With Bevacizumab Followed by Randomized Study of the Maximum Tolerated Dose of TPI 287 in Combination With Bevacizumab Versus Bevacizumab Alone in Adults With Recurrent GlioblastomaStatus: , Estimated PCD: 2024-11-01
Clinical trial
A Randomized, Phase I/II Trial of Irinotecan and Temozolomide Compared to Irinotecan and Temozolomide in Combination With TPI 287 in Patients With Primary Refractory or Early Relapsed NeuroblastomaStatus: Terminated, Estimated PCD: 2014-12-01
Clinical trial
A Phase I/II Trial of TPI-287 in Patients With Refractory or Recurrent Neuroblastoma and MedulloblastomaStatus: Terminated, Estimated PCD: 2014-12-01